top of page
H+ channel inhibitors as anti-cancer drugs
Developing innovative therapeutics by targeting pathways based on 30+ years of research at the University of Geneva
HPlus is developing innovative therapeutics by targeting pathways based on more than 30 years of research at the University of Geneva. The company’s sole focus is the study of the Hv1 proton channel.
1.4 million CHF of grant funding already raised. HPlus is now seeking 1 million CHF to continue HIT to LEAD phase and to secure IP protection. First disease indication: Granulocytic Sarcome
Dr. Zhukovsky, Dr. Niquille,
Dr. Brun, Dr. Mosser
bottom of page